Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by airway hyper-responsiveness (AHR) and airflow obstruction. The National Asthma Education and Prevention Program (NAEPP) guidelines established a number of asthma management goals that focus on achieving and maintaining asthma control [1] . Asthma control is achieved by minimizing impairment, risk of exacerbations, lung function decline and adverse effects [1] . To achieve these goals, a six-step pharmacological algorithm for treatment of asthma has been recommended. b 2 -Adrenoceptor (AR) agonists are the most powerful known bronchodilators and play a pivotal role in every step of this algorithm. Whereas these agents were first used many years ago, progress in drug development has resulted in more well tolerated, longer-acting and b 2 -AR-specific agents [2] . b 2 -AR agonists act by binding to the b 2 -AR, which is a member of the seven transmembrane domain, G-protein-coupled family of receptors (GPCRs). Although b 2 -ARs are present in high density in airway smooth muscle cells, they are also present in a multitude of other tissues and cell types including submucosal glands, airway epithelial cells, vascular endothelium, mast cells, circulating inflammatory cells such as eosinophils and lymphocytes, type II pneumocytes and cholinergic ganglia. Therefore, these agents may have other potential nonbronchodilator effects such as anti-inflammatory properties [3] , although the clinical implications of such effects are still debatable [4 ] . Numerous b 2 -AR agonists of differing pharmacologic properties are available for clinical use and several more are currently in development for use either as stand-alone drugs [5 ] or in combination with inhaled corticosteroids Purpose of review b 2 -Adrenoceptor (AR) agonists are the most effective bronchodilators known, and play important roles in every step of asthma therapy. Intrinsic efficacy is an important pharmacological property that differentiates the clinical effects and safety profile of b 2 -AR agonists. We review the role of b 2 -AR agonist intrinsic efficacy in asthma treatment focusing on recent literature.
Recent findings
In acute asthma, a full agonist (high intrinsic efficacy) offers a clinical advantage over a partial agonist (low intrinsic efficacy) but with the potential of inducing dose-dependent adverse effects. The chronic use of b 2 -AR agonists may be associated with several adverse outcomes including loss of asthma control and even increased mortality. Recently, the role of b-AR inverse agonists (beta-blockers) which have a negative intrinsic efficacy was studied. Whereas contraindicated in acute asthma, preliminary data suggest that the chronic use of these agents may be associated with attenuation of airway hyper-responsiveness in patients with mild asthma. Studies in a murine model of asthma suggest that such effects may be related to decreased airway inflammation and mucous metaplasia. Summary Rational choice among b 2 -AR agonists in acute and chronic asthma should be influenced by differences in intrinsic efficacy among these agents. In acute severe asthma, a full agonist offers a clinical advantage over a partial agonist. Whereas the use of inverse agonists in the treatment of asthma is still experimental and needs further exploration in future trials, preliminary studies suggest that their chronic use is well tolerated and is associated with decreased airway hyper-responsiveness. [6] . Clinicians typically base their choice of a particular agent on parameters of receptor selectivity, onset and duration of action, but rarely consider another very important pharmacologic characteristic -the intrinsic efficacy.
Keywords
Pharmacologic differences among b-AR agonists b 2 -AR agonists are classified by their onset and duration of action, receptor selectivity, affinity, potency and efficacy [2] . The onset of action of inhaled b 2 -AR agonists is primarily influenced by their lipophilicity (the higher the lipophilicity the slower onset of action) and kinetics of binding. Among the agents currently in use, albuterol and formoterol have a more rapid onset of action than salmeterol. Duration of action is similarly influenced by lipophilicity and binding kinetics, as well as by resistance to clearance. Both salmeterol and formoterol have a longer duration of action than albuterol as their lipophilicity produces a depot effect at the cell membrane allowing their twice daily administration. Receptor selectivity is also an important pharmacologic characteristic; however, all currently used b 2 -AR agonists are moderately to highly selective for the b 2 -AR. Affinity refers to the attraction between the agonist and its receptor and is most commonly expressed as the dissociation constant between agonist and receptor. Potency refers to the concentration of a drug that achieves the half maximal response of which that drug is capable (EC 50 ), and is dependent upon the affinity and intrinsic efficacy of the drug.
Intrinsic efficacy refers to the ability of a drug to activate its receptor, without regard for drug concentration or receptor numbers as it is defined as efficacy/total receptor number [2] . Receptor activation may be measured as a conformational change by physical techniques, as a biochemical response to activation of the signal transduction pathway downstream of the receptor, or as a physiologic response. Measured efficacy depends on variable factors in the target cell, such as receptor number or the presence of functional antagonism (i.e. activation of an opposing signal transduction pathway). In a cell with high receptor numbers, activation of only a small fraction of receptors suffices to generate a full response to high efficacy drugs. Conversely, in a cell with low receptor number or in the presence of functional antagonism, activation of even a high fraction of receptors may not yield a full relaxation response.
To better understand the differences between full, partial and inverse agonists, it is useful to consider the two-state receptor model. GPCRs are thought to exist in an equilibrium between an inactive conformation (R) and a spontaneously active conformation (R Ã ), Classic agonists have a high affinity for R Ã relative to their affinity for R and increase the concentration of R Ã . In this model intrinsic efficacy is defined as the relative affinity preference of ligands for R and R Ã (Fig. 1 ). Highly efficacious drugs (full agonists) have much higher affinity for R Ã than R, whereas agonists with low intrinsic efficacy (partial agonists) have a relatively small affinity preference for R Ã relative to R. Among currently available b 2 -AR agonists, epinephrine has the highest intrinsic efficacy followed by formoterol then by albuterol and finally salmeterol which has the lowest intrinsic efficacy. It is of interest that almost all novel b 2 -AR agonists under development have a high intrinsic efficacy comparable with that of formoterol [5 ] . In this model, inverse agonists (negative intrinsic efficacy) have a high affinity for the R conformation relative to the R Ã and decrease the concentration of the R Ã , exerting the exact opposite effects of agonists. Finally, neutral competitive antagonists have equal affinity for R and R Ã and do not displace the equilibrium but competitively antagonize the effects of both agonists and inverse agonists ( Fig. 1) [7] .
Full vs. partial b 2 -AR agonists in asthma
Because b 2 -AR agonists can act rapidly and are the most effective bronchodilators available, their use is a cornerstone of the initial management of acute asthma exacerbations. The severity of acute asthma ranges from mild exacerbations that readily respond to initial therapy in the emergency department, to severe, life-threatening exacerbations requiring intubation and admission to the intensive care unit [8] . Therefore, a single agent, a ). This is more pronounced with a full agonist than with a partial agonist. When an antagonist is added (in the absence of an agonist), it produces no effect (intrinsic efficacy ¼ 0). However, if an inverse agonist is added, it inhibits the constitutive (basal) activity of the receptor (negative intrinsic efficacy) and shifts the receptor away from the active conformation (R Ã ) to the inactive conformation (R).
standard dose, and a particular route of delivery are not appropriate for all settings. In the majority of cases, an inhaled rescue drug such as albuterol, given more frequently and in higher doses than for simple rescue, will suffice. However, in a patient with impending respiratory failure despite the administration of high doses of a rescue medication, when b 2 -ARs are desensitized by prior use of b 2 -agonists and functionally antagonized by inflammatory mediators that are present during an acute exacerbation, a full agonist (high efficacy) has advantages over a partial agonist (low efficacy) ( Fig. 2 ) [9 ,10,11] . In the chronic setting, agonists of high intrinsic efficacy such as formoterol have dose-dependent effects on bronchoprotection, an effect that is not seen with salmeterol [12] .
Safety of b 2 -AR agonists in asthma
Adverse effects of b 2 -AR agonists are largely due to activation of b 2 -AR in nontarget tissues. Cardiac stimulation leads to tachycardia and arrhythmias, whereas skeletal muscle stimulation leads to tremor and hypokalemia. Nontarget tissues, such as skeletal muscle and the heart, have a lower b 2 -AR density than airway smooth muscle. This accounts, in part, for the excellent sideeffect profile of partial agonists such as albuterol, because there are sufficient spare receptors in the target tissue for full cell activation by a partial agonist but not in nontarget tissues [2] . Furthermore, the desensitization that occurs during the first few days of regular use of a b 2 -AR agonist results in further reduction in the responsiveness of nontarget tissues, accounting for the commonly observed resolution of side-effects, such as tachycardia and tremor, after the first few doses. In view of the low receptor density of nontarget tissues, it might be expected that full b 2 -AR agonists would elicit a response greater than partial agonists in nontarget tissues, and this is indeed the case.
In dose-response studies, full agonists with high intrinsic efficacy have been demonstrated to be capable of causing more adverse effects, such as greater tachycardia and reduction in serum potassium, than partial agonists [12] [13] [14] . Tolerance to the bronchoprotective properties of b 2 -AR agonists and modest but nonprogressive tolerance to their bronchodilator effects have been seen. The regular use of short-acting b 2 -AR agonists has been associated with increased AHR, loss of asthma control and even increased asthma mortality [15 ] . Recent data show similar associations with regular use of long-acting b 2 -AR. It is of interest that the most dramatic spikes in asthma mortality were observed with the use of high-dose formulations of b 2 -AR agonists of high intrinsic efficacy, isoproterenol and fenoterol [15 ] . These adverse effects may be more pronounced in certain individuals with homozygous arginine genotype at position 16 of the b 2 -AR (one-sixth of Caucasians and one-fifth of African-Americans in the US) [16, 17] .
More recently, the safety of regular use of long-acting b 2 -AR agonists (both low and high intrinsic efficacy agents) has also been questioned [18,19 ,20,21] . This issue was amplified by the results of a study (SMART) which suggested an association between the regular use of salmeterol and increased asthma-related death and lifethreatening experiences [22] . Other studies questioned the safety of formoterol in asthma [23] and a recent metaanalysis did not have enough power to rule out any signal of increased mortality with formoterol [24 ] . On the contrary, several observational studies failed to confirm these findings in patients treated with long-acting b 2 -AR agonists who are taking inhaled corticosteroids [25] [26] [27] [28] 29 ] .
The exact mechanisms for this safety issue with chronic use of b 2 -AR agonists in asthma remain unknown. Potential mechanisms include an increase in airway inflammation [30] , AHR [31, 32 ] , competitive antagonism of the b 2 -AR causing subsensitivity to albuterol [33] and an increase in brain-derived neurotrophic factor (BDNF) [32 ] . Furthermore, although some studies suggested that adverse effects occur more frequently in some patients with homozygous arginine 16 genotype [34] [35] [36] , other studies failed to confirm this observation with the use of long-acting b 2 -AR agonists [37, 38] .
Inverse b-AR agonists (b-blockers) in asthma
Inverse agonists exert opposite effects to agonists. However, the clinical effects of agonists and inverse agonists are highly dependent on the duration of therapy [39] Intrinsic efficacy of b-adrenoceptor drugs in asthma Hanania et al. 3 Figure 2 Schematic representation for the potential differential effects between full and partial b 2 -AR agonists on airway smooth muscles during remission and during an acute severe exacerbation of asthma ( Fig. 3 ). This paradox was first described in congestive heart failure (CHF) when the acute administration of a b-AR agonist is beneficial; however, its chronic administration is deleterious to cardiac function and increases mortality. The opposite occurs with the use of an inverse agonist (b-blocker), which has an acute deleterious effect but chronically beneficial effect on survival [40] . The same analogy is observed with b 2 -AR agonists in asthma, when their acute administration is beneficial to lung function and symptoms but their chronic use is associated with loss of asthma control and increased mortality. Inverse agonists are currently contraindicated in asthma and thus are underutilized in this population, even in those patients with cardiac risk factors who may benefit from them [41 ] . This results from the fact that the acute administration of these drugs can produce bronchoconstriction and worsening of asthma symptoms [40] . However, several recent studies demonstrated the safety and potential beneficial effects of cardioselective beta-blockers when administered to treat cardiac comorbidities in patients with asthma or chronic obstructive pulmonary disease [42] [43] [44] [45] . The effects of chronic administration of inverse b-agonists in the treatment of asthma have remained unknown until recently. Recent studies using a murine model of asthma showed that whereas acute (single dose) administration of b-AR inverse agonists increased AHR, their chronic (28 day) administration had an opposite effect and decreased AHR [31] . Furthermore, chronic treatment with b-AR inverse agonists produces broad anti-inflammatory effects, and especially dramatic effects on airway epithelium and mucous metaplasia [46 ,47 ] . These results have been confirmed using b 2 -AR null mice, demonstrating a pivotal role of the b 2 -AR for full development of mucous metaplasia and other features of asthma [48 ] . In human asthma, the effect of chronic administration of the inverse b-AR agonist, nadolol, on AHR in 10 patients with mild asthma was recently reported [49 ] . Nadolol produced a dosedependent increase in the PC 20 methacholine. The significance of these above findings in animal models and human patients, if confirmed in additional studies, may provide a paradigm shift in the chronic management of asthma [50] [51] [52] .
Conclusion
Intrinsic efficacy is a key pharmacologic parameter that differs dramatically among available b-agonists. b 2 -AR agonists of high intrinsic efficacy offer advantages over weak agonists in emergency management of asthma though their use is associated with dose-dependent adverse effects. The long-term use of both short-acting and long-acting b 2 -AR agonists, especially when used without concomitant steroids, can be associated with worsening asthma control, increased AHR and increased mortality. b-AR inverse agonists may have beneficial effects in the chronic treatment of asthma but this needs further evaluation. 
